Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.
Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.
复制标题
DOI：
10.1007/s00213-020-05710-w
复制
发表时间：
2021-03
影响因子：
3.4
通讯作者：
Holland J
中科院分区：
文献类型：
--
作者：
Feduccia AA;Jerome L;Mithoefer MC;Holland J
MDMA 辅助心理治疗作为一种治疗创伤后应激障碍 (PTSD) 的新型疗法正在接受研究。 MDMA 的主要作用机制涉及与通常用于治疗 PTSD 的抗抑郁药物所针对的相同的再摄取转运蛋白。数据来自四项 MDMA 辅助心理治疗的 2 期试验。为了探索逐渐减少抗抑郁药物的效果，被随机接受活性剂量 MDMA (75–125 mg) 的参与者被分为两组（逐渐减量组 (n = 16) 或非逐渐减量组 (n = 34)）。对基线和主要终点的 PTSD 和抑郁症状严重程度以及两次 MDMA 治疗期间的峰值生命体征进行了组间比较。减量组和非减量组之间的人口统计学、基线创伤后应激障碍 (PTSD) 和抑郁严重程度相似。在主要终点，与逐渐减量组（平均值= 70.3，SD = 33.60）相比，非逐渐减量组（平均值 = 45.7，SD = 27.17）的CAPS-IV总分显着（p = 0.009）较低。非逐渐减量组中更多的参与者 (63.6%) 在主要终点上不再符合 PTSD 标准，而减量组中的参与者 (25.0%) 则更多。与逐渐减量组（平均值= 22.6，SD = 16.69）相比，非逐渐减量组（平均值 = 12.7，SD = 10.17）的抑郁症状严重程度评分较低（p = 0.010）。各组之间的峰值收缩压（p = 0.043）和舒张压（p = 0.032）存在显着差异。最近接触针对再摄取转运蛋白的抗抑郁药物可能会降低对 MDMA 辅助心理治疗的治疗反应。在线版本包含可在 10.1007/s00213-020-05710-w 获取的补充材料。
MDMA-assisted psychotherapy is under investigation as a novel treatment for posttraumatic stress disorder (PTSD). The primary mechanism of action of MDMA involves the same reuptake transporters targeted by antidepressant medications commonly prescribed for PTSD. Data were pooled from four phase 2 trials of MDMA-assisted psychotherapy. To explore the effect of tapering antidepressant medications, participants who had been randomized to receive active doses of MDMA (75–125 mg) were divided into two groups (taper group (n = 16) or non-taper group (n = 34)). Between-group comparisons were made for PTSD and depression symptom severity at the baseline and the primary endpoint, and for peak vital signs across two MDMA sessions. Demographics, baseline PTSD, and depression severity were similar between the taper and non-taper groups. At the primary endpoint, the non-taper group (mean = 45.7, SD = 27.17) had a significantly (p = 0.009) lower CAPS-IV total scores compared to the taper group (mean = 70.3, SD = 33.60). More participants in the non-taper group (63.6%) no longer met PTSD criteria at the primary endpoint than those in the taper group (25.0%). The non-taper group (mean = 12.7, SD = 10.17) had lower depression symptom severity scores (p = 0.010) compared to the taper group (mean = 22.6, SD = 16.69). There were significant differences between groups in peak systolic blood pressure (p = 0.043) and diastolic blood pressure (p = 0.032). Recent exposure to antidepressant drugs that target reuptake transporters may reduce treatment response to MDMA-assisted psychotherapy. The online version contains supplementary material available at 10.1007/s00213-020-05710-w.
登录
查看更多内容
影响因子：
6.9
作者：
Koenen KC;Ratanatharathorn A;Ng L;McLaughlin KA;Bromet EJ;Stein DJ;Karam EG;Meron Ruscio A;Benjet C;Scott K;Atwoli L;Petukhova M;Lim CCW;Aguilar-Gaxiola S;Al-Hamzawi A;Alonso J;Bunting B;Ciutan M;de Girolamo G;Degenhardt L;Gureje O;Haro JM;Huang Y;Kawakami N;Lee S;Navarro-Mateu F;Pennell BE;Piazza M;Sampson N;Ten Have M;Torres Y;Viana MC;Williams D;Xavier M;Kessler RC
通讯作者：
Kessler RC
DOI：
10.1177/0269881110378371
发表时间：
2011-04
期刊：
Journal of psychopharmacology (Oxford, England)
影响因子：
--
作者：
Mithoefer MC;Wagner MT;Mithoefer AT;Jerome L;Doblin R
通讯作者：
Doblin R
DOI：
10.4161/23328940.2014.955433
发表时间：
2014-10
期刊：
Temperature (Austin, Tex.)
影响因子：
--
作者：
Liechti ME
通讯作者：
Liechti ME
影响因子：
3.4
作者：
Hysek, Cedric M.;Domes, Gregor;Liechti, Matthias E.
通讯作者：
Liechti, Matthias E.
影响因子：
4.1
作者：
Oehen, Peter;Traber, Rafael;Schnyder, Ulrich
通讯作者：
Schnyder, Ulrich